A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol

Background Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal networks in...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer Vol. 24; no. 1; pp. 82 - 7
Main Authors: Mastall, Maximilian, Roth, Patrick, Bink, Andrea, Fischer Maranta, Angela, Läubli, Heinz, Hottinger, Andreas Felix, Hundsberger, Thomas, Migliorini, Denis, Ochsenbein, Adrian, Seystahl, Katharina, Imbach, Lukas, Hortobagyi, Tibor, Held, Leonhard, Weller, Michael, Wirsching, Hans-Georg
Format: Journal Article
Language:English
Published: London BioMed Central 15.01.2024
BioMed Central Ltd
Springer Nature B.V
BMC
Subjects:
ISSN:1471-2407, 1471-2407
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first